ATE516817T1 - Impfstoffe zur immunisierung gegen helicobacter - Google Patents

Impfstoffe zur immunisierung gegen helicobacter

Info

Publication number
ATE516817T1
ATE516817T1 AT06754304T AT06754304T ATE516817T1 AT E516817 T1 ATE516817 T1 AT E516817T1 AT 06754304 T AT06754304 T AT 06754304T AT 06754304 T AT06754304 T AT 06754304T AT E516817 T1 ATE516817 T1 AT E516817T1
Authority
AT
Austria
Prior art keywords
vaccines
immunization against
against helicobacter
helicobacter
immunization
Prior art date
Application number
AT06754304T
Other languages
English (en)
Inventor
Richard Ducatelle
Ann Hellemans
Original Assignee
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gent filed Critical Univ Gent
Application granted granted Critical
Publication of ATE516817T1 publication Critical patent/ATE516817T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06754304T 2005-06-16 2006-06-12 Impfstoffe zur immunisierung gegen helicobacter ATE516817T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69139405P 2005-06-16 2005-06-16
US69599505P 2005-07-01 2005-07-01
PCT/EP2006/005616 WO2006133879A2 (en) 2005-06-16 2006-06-12 Vaccines for immunization against helicobacter

Publications (1)

Publication Number Publication Date
ATE516817T1 true ATE516817T1 (de) 2011-08-15

Family

ID=37309206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754304T ATE516817T1 (de) 2005-06-16 2006-06-12 Impfstoffe zur immunisierung gegen helicobacter

Country Status (9)

Country Link
US (1) US7780951B2 (de)
EP (1) EP1896067B1 (de)
JP (1) JP2008546658A (de)
AR (1) AR054477A1 (de)
AT (1) ATE516817T1 (de)
AU (1) AU2006257383A1 (de)
CA (1) CA2612271A1 (de)
TW (1) TW200800255A (de)
WO (1) WO2006133879A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790143B2 (en) 2005-06-16 2010-09-07 Universiteit Gent Vaccines for immunization against helicobacter
ATE516817T1 (de) 2005-06-16 2011-08-15 Univ Gent Impfstoffe zur immunisierung gegen helicobacter
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
US7939079B2 (en) 2006-11-14 2011-05-10 Universiteit Gent Helicobacter species and cultivation thereof
CN103667127A (zh) * 2006-11-14 2014-03-26 根特大学 螺杆菌的体外培养
GB0807306D0 (en) * 2008-04-22 2008-05-28 Univ Ghent Adjuvants for use in vaccination
GB0807305D0 (en) * 2008-04-22 2008-05-28 Univ Ghent Compounds for use in therapy
US20110105383A1 (en) * 2008-09-10 2011-05-05 Magnus Hook Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
KR101856462B1 (ko) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
WO2012016429A1 (en) * 2010-08-03 2012-02-09 Asia Hepato Gene Co. Compositions and methods for treating hepatitis virus infection
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
CN119236063A (zh) * 2013-06-21 2025-01-03 翁德克控股有限公司 免疫治疗组合物及其用途
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
EP1599164B1 (de) * 2003-02-03 2015-04-08 Cerebus Biologicals, Inc. Verfahren zur behandlung, vorbeugung und nachweis von helicobacter-infektionen
DE102005025467A1 (de) 2005-06-02 2006-12-07 Westfaliasurge Gmbh Verfahren zum Melken von Tieren in einer Gruppe
ATE516817T1 (de) 2005-06-16 2011-08-15 Univ Gent Impfstoffe zur immunisierung gegen helicobacter

Also Published As

Publication number Publication date
US20060292179A1 (en) 2006-12-28
AU2006257383A1 (en) 2006-12-21
WO2006133879A2 (en) 2006-12-21
JP2008546658A (ja) 2008-12-25
CA2612271A1 (en) 2006-12-21
EP1896067A2 (de) 2008-03-12
WO2006133879A3 (en) 2007-07-26
US7780951B2 (en) 2010-08-24
TW200800255A (en) 2008-01-01
EP1896067B1 (de) 2011-07-20
AR054477A1 (es) 2007-06-27

Similar Documents

Publication Publication Date Title
HUS2200002I1 (hu) Immunogén készítmény
ATE462445T1 (de) Prrs-impfstoffe
DK1968631T3 (da) Vaccine
ATE450271T1 (de) Impfstoff
ATE516044T1 (de) Attenuierte rotavirus-vakzine zur oralen verabreichung
BRPI0814594A2 (pt) Composições e métodos adjuvantes de antígeno
DK2049559T3 (da) Forbedrede HPV vacciner
DK1959991T3 (da) Terapeutisk vaccine
DK2068918T4 (da) Vaccinesammensætning omfattende syntetisk adjuvant
GB0504436D0 (en) Vaccine
CR10571A (es) Vacuna virica recombinante
MA28609B1 (fr) Vaccins
MA28639B1 (fr) Vaccins
BRPI0607474A2 (pt) vacinação enriquecida com glicosido-alquila
DE602006011096D1 (de) Flanschverbindungsvorrichtung
EP2061502A4 (de) Kohlenhydrat-basierte impfstoffe für hlv
EP2016414A4 (de) T-zell vakzin
EP2015785A4 (de) Agrm2-antigen
DE602006003359D1 (de) Gerät zur optischen Tomographie
ZA200709207B (en) Vaccine
EP1948782A4 (de) Impfstoffadjuvantien
GB0810662D0 (en) Vaccine
GB0515135D0 (en) Vaccine
GB0516944D0 (en) Vaccine
ZA200709210B (en) Vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties